SGLT2 inhibitors and their role in reducing adiposopathy and inflammation in diabetes and non-diabetes CKD patients
SGLT2i treatment, and particularly dapagliflozin, modulates both adiposopathy and systemic inflammation while slowing down renal function loss, demonstrating benefits for CKD patients regardless of diabetes status.
Authors
- C Pires Ana
- Desiré Luis
- Sonia Muñoz Pilar
- Antonio Bellasi (ORCID: https://orcid.org/0000-0001-7830-1645)
- OH Okojie (ORCID: https://orcid.org/0009-0001-6805-7738)
- Steib Nelia
- Fortea Isabel
Institutions
- University of Alberta (CA)
- Aston University (GB)
- Universidad Cardenal Herrera CEU (ES)
- Ospedale regionale di Lugano (CH)
- Hospital General Universitario De Valencia (ES)
Publication Details
- Journal
- International Urology and Nephrology
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1007/s11255-025-04965-6
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00